Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
Abstract The successful treatment of schizophrenia entails improvement across a spectrum of symptoms. The aim of this post hoc analysis was to characterize the short- and long-term effects of brexpiprazole on Positive and Negative Syndrome Scale (PANSS) ‘Marder factors.’ Data were
Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies
Abstract Background: The treatment of patients with severe schizophrenia symptoms can be complicated and expensive. להמשך קריאה Nicole Meade et al., J Psychopharmacol. 2020 Aug; 34(8): 829–838. Published online 2020 Jul 10. doi: 10.1177/0269881120936485
Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
Conclusions: Brexpiprazole has the potential to be an efficacious and well-tolerated treatment for agitation and hostility among patients with schizophrenia.
Effect of Brexpiprazole on Prolactin. An Analysis of Short- and Long-Term Studies in Schizophrenia
Abstract Background Hyperprolactinemia is an undesirable effect of most antipsychotics because of D2-receptor blockade. We assessed the effect of the D2-receptor partial agonist brexpiprazole on prolactin, based on pooled data from three 6-week, randomized, placebo-controlled studies and two open-label extension
Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies
Abstract Objective: To analyze the effect of brexpiprazole on metabolic parameters and body weight in adults with schizophrenia, including clinically relevant sub-groups of patients, based on data from two pivotal phase 3 studies (NCT01393613; NCT01396421) and a long-term extension study (NCT01397786). להמשך
Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies
Abstract Brexpiprazole, a serotonin-dopamine activity modulator, is a partial agonist at 5-HT1A and dopamine D2 receptors, and antagonist at 5-HT2A and noradrenaline α1B and α2C receptors, all at similar potency. Efficacy of brexpiprazole was evaluated in patients with acutely exacerbated schizophrenia in three short-term, randomized, double-blind, placebo-controlled studies. להמשך קריאה Christoph U.
Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm
Implications/conclusions: Differences in tolerability profiles regarding activation and sedation have implications in terms of selecting the optimal antipsychotic for a given individual.
Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
Abstract Background: Brexpiprazole has previously demonstrated efficacy in acute schizophrenia trials. The objective of this trial was to assess the efficacy, safety, and tolerability of maintenance treatment with brexpiprazole in adults with schizophrenia. להמשך קריאה Fleischhacker WW, Hobart M, Ouyang J,
The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study
Abstract The aim of this study was to evaluate flexibly dosed brexpiprazole for early-episode schizophrenia through the assessment of efficacy, social functioning, and tolerability. This was an exploratory, 16-week, open-label, flexible-dose (1, 2, 3, or 4 mg/day; target dose 3 mg/day) study
Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia
Abstract Second-generation antipsychotics have demonstrated efficacy for patients with schizophrenia but are associated with wide-ranging side effects. Brexpiprazole, a serotonin-dopamine activity modulator, has demonstrated efficacy in adult patients with schizophrenia. להמשך קריאה John M. Kane et al., Schizophrenia Research, Volume 174, Issues 1–3, 2016, Pages
Mechanism of action of brexpiprazole: comparison with aripiprazole
Abstract Brexpiprazole is a new therapeutic agent that was recently approved for the treatment of schizophrenia and for the adjunctive treatment of major depressive disorder. Brexpiprazole has features that both overlap and contrast with a related molecule, aripiprazole, and these
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator
Abstract Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug candidate in clinical development for psychiatric disorders with high affinity for serotonin, dopamine, and noradrenaline receptors. להמשך קריאה Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H,
Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
Abstract The successful treatment of schizophrenia entails improvement across a spectrum of symptoms. The aim of this post hoc analysis was to characterize the
Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies
Abstract Background: The treatment of patients with severe
Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
Conclusions: Brexpiprazole has the potential to be
Effect of Brexpiprazole on Prolactin. An Analysis of Short- and Long-Term Studies in Schizophrenia
Abstract Background Hyperprolactinemia is an undesirable effect of
Changes in metabolic parameters and body weight in brexpiprazole-treated patients with acute schizophrenia: pooled analyses of phase 3 clinical studies
Abstract Objective: To analyze the effect of brexpiprazole on
Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies
Abstract Brexpiprazole, a serotonin-dopamine activity modulator, is a partial
Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm
Implications/conclusions: Differences in tolerability profiles regarding activation
Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
Abstract Background: Brexpiprazole has previously demonstrated efficacy in acute
The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study
Abstract The aim of this study was to
Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia
Abstract Second-generation antipsychotics have demonstrated efficacy for patients with schizophrenia but are
Mechanism of action of brexpiprazole: comparison with aripiprazole
Abstract Brexpiprazole is a new therapeutic agent that
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator
Abstract Brexpiprazole (OPC-34712, 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one) is a novel drug